Skip to main content

Table 1 Overview of previously reported cases of brivaracetam during pregnancy and childbirth in women with epilepsy

From: Brivaracetam and topiramate serum levels during pregnancy and delivery: a case report and a review of literature

Authors

Cases

BRV/d

Further ASM/d

Conc. of BRV during pregnancy

Conc. of BRV in umbilical cord

Conc. of BRV postpartum)

Serum ratio (infant/mother)

Newborn malformation

Paolini et al. [15]

3

P1*: 100 mg

P2: 150 mg

P3: 200 mg

None

None

P3: LTG 450 mg

Congenital dermal melanocytosis and ankyloglossia

Infantile hemangioma on thumb and back

None

Landmark et al. [11]

2

P 1: 150 mg

P2: 200 mg

P1: none

P2: PER 8 mg, LCM 400 mg

P1: 3,8 umol/l

**(0.81 mg/l)

P2: 6,6 umol/l

**(1.40 mg/l)

Twin 1: 4,1 umol/l

**(0.87 mg/l)

Twin 2: 4,2 umol/l

**(0.89 mg/l)

P2: 1, 2umol/l

**(0.25 mg/l)

P1: 4,4 umol/l

**(0.93 mg/l)

P2: 6,1 umol/l

**(1.29 mg/l)

1.08

1.11

0.18

None

None

None

Navarro [14]

1

200 mg

none

None

  1. *P1 = Patient 1, P2 = Patient 2, BRV = brivaracetam, ASM = antiseizure medication, LTG = lamotrigine, PER = perampanel, LCM = lacosamide
  2. **For better comparability of the data, the amount of substance was converted into weight units